Literature DB >> 11278833

Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.

S Liu1, T H Bugge, S H Leppla.   

Abstract

Urokinase plasminogen activator receptor (uPAR) binds pro-urokinase plasminogen activator (pro-uPA) and thereby localizes it near plasminogen, causing the generation of active uPA and plasmin on the cell surface. uPAR and uPA are overexpressed in a variety of human tumors and tumor cell lines, and expression of uPAR and uPA is highly correlated to tumor invasion and metastasis. To exploit these characteristics in the design of tumor cell-selective cytotoxins, we constructed mutated anthrax toxin-protective antigen (PrAg) proteins in which the furin cleavage site is replaced by sequences cleaved specifically by uPA. These uPA-targeted PrAg proteins were activated selectively on the surface of uPAR-expressing tumor cells in the presence of pro-uPA and plasminogen. The activated PrAg proteins caused internalization of a recombinant cytotoxin, FP59, consisting of anthrax toxin lethal factor residues 1-254 fused to the ADP-ribosylation domain of Pseudomonas exotoxin A, thereby killing the uPAR-expressing tumor cells. The activation and cytotoxicity of these uPA-targeted PrAg proteins were strictly dependent on the integrity of the tumor cell surface-associated plasminogen activation system. We also constructed a mutated PrAg protein that selectively killed tissue plasminogen activator-expressing cells. These mutated PrAg proteins may be useful as new therapeutic agents for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278833     DOI: 10.1074/jbc.M011085200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

Review 1.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

2.  Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging.

Authors:  Lily Yang; Zehong Cao; Hari Krishna Sajja; Hui Mao; Liya Wang; Huaying Geng; Hengyi Xu; Tieshan Jiang; William C Wood; Shuming Nie; Y Andrew Wang
Journal:  J Biomed Nanotechnol       Date:  2008-12-01       Impact factor: 4.099

3.  Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.

Authors:  Kuang-Hua Chen; Shihui Liu; Laurie A Bankston; Robert C Liddington; Stephen H Leppla
Journal:  J Biol Chem       Date:  2007-01-24       Impact factor: 5.157

4.  Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.

Authors:  Shihui Liu; Thomas H Bugge; Arthur E Frankel; Stephen H Leppla
Journal:  Methods Mol Biol       Date:  2009

5.  Solid tumor therapy by selectively targeting stromal endothelial cells.

Authors:  Shihui Liu; Jie Liu; Qian Ma; Liu Cao; Rasem J Fattah; Zuxi Yu; Thomas H Bugge; Toren Finkel; Stephen H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

Review 6.  Obstructing toxin pathways by targeted pore blockage.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Chem Rev       Date:  2012-10-11       Impact factor: 60.622

7.  Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.

Authors:  Elyse S Fischer; Warren A Campbell; Shihui Liu; Rodolfo Ghirlando; Rasem J Fattah; Thomas H Bugge; Stephen H Leppla
Journal:  Protein Sci       Date:  2019-04-17       Impact factor: 6.725

8.  Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.

Authors:  Ying Xiang; Qiying Li; Dehong Huang; Xianjun Tang; Li Wang; Yang Shi; Wenjun Zhang; Tao Yang; Chunyan Xiao; Jianghong Wang
Journal:  Exp Biol Med (Maywood)       Date:  2014-08-14

9.  Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.

Authors:  Alexander N Wein; Shihui Liu; Yi Zhang; Andrew T McKenzie; Stephen H Leppla
Journal:  Invest New Drugs       Date:  2012-07-28       Impact factor: 3.850

10.  Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.

Authors:  Ping Jun Zhu; John P Hobson; Noel Southall; Cunping Qiu; Craig J Thomas; Jiamo Lu; James Inglese; Wei Zheng; Stephen H Leppla; Thomas H Bugge; Christopher P Austin; Shihui Liu
Journal:  Bioorg Med Chem       Date:  2009-05-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.